GRITSYSTEMS AS

Their core work

GRITSYSTEMS AS is a Danish specialist SME that brings quantitative and analytical methods to antibacterial drug development programs. They contribute expertise in clinical trial design, statistical analysis, and preclinical-to-clinical development frameworks within large international research consortia. Their work covers the full early development arc: from designing animal infection model experiments to building statistical architectures for Phase II/III trials targeting resistant bacterial pathogens. Based in Valby near Copenhagen — a strong pharma and biotech hub — they function as a specialist analytical partner rather than a drug developer themselves.

What they specialise in

How they've shifted over time

In their first H2020 project (COMBINE, 2019), GRITSYSTEMS focused on broad methodological capabilities — clinical trial design, animal infection models, and drug discovery frameworks applicable across multiple resistant bacterial pathogens. Their second project (ERA4TB, 2020) shows a sharper disease-area focus, narrowing to tuberculosis specifically and shifting emphasis toward preclinical development and pan-TB combination regimen work. The trajectory points from general antibacterial methodology toward TB as a specialized disease area, likely reflecting both market demand and accumulated expertise in the TB drug pipeline.

GRITSYSTEMS appears to be deepening its position in the TB drug development pipeline, making them a relevant partner for any future EU or global health initiative targeting drug-resistant tuberculosis or pan-TB combination regimens.

How they like to work

GRITSYSTEMS has participated exclusively as a consortium partner — never as a coordinator — across both H2020 projects. They work within large, internationally distributed consortia (43 unique partners across 13 countries), which suggests they are comfortable operating as one specialist node in complex multi-partner programs. This profile — specialist contributor in large consortia, no leadership role yet — is typical of SMEs that provide a well-defined technical service rather than driving the scientific agenda.

GRITSYSTEMS has built a notably wide network for a two-project SME: 43 unique partners spanning 13 countries, consistent with participation in large RIA consortia like ERA4TB, which typically involve 15–30 institutions across Europe and beyond. Their geographic footprint is European in scope, likely anchored around major EU pharma and academic hubs.

What sets them apart

GRITSYSTEMS occupies an unusual niche for a Danish SME: they bring analytical and systems-level rigor to early-phase antibacterial and TB drug development, a space usually dominated by large CROs or academic biostatistics groups. Their participation in both COMBINE and ERA4TB — two of the most significant EU-funded antibacterial drug programs — gives them credibility and direct exposure to the regulatory and scientific standards required for MDR pathogen programs. For a consortium builder, they offer specialist trial design and preclinical analytical capacity without the overhead of a large CRO.

Highlights from their portfolio

• ERA4TB
  Largest funding received (EUR 1,132,500) and focused on the high-priority global health challenge of pan-TB regimen development, placing GRITSYSTEMS at the center of Europe's most ambitious tuberculosis drug acceleration program.
• COMBINE
  Longest project timeline (2019–2027) and broadest methodological scope, covering clinical trial design, animal infection models, and drug discovery for MDR bacterial infections — demonstrating GRITSYSTEMS' foundational capabilities across the antibacterial development pipeline.